ArticleInternational journal of molecular sciences2013
Innovative therapeutic strategies in the treatment of brain metastases.
Article in International journal of molecular sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis.Journal of neuro-oncology · 2018Pooled it
- The efficacy and limitations of stereotactic radiosurgery as a salvage treatment after failed whole brain radiotherapy for brain metastases.Journal of neuro-oncology · 2013Trial
- Tumor Microenvironment in Melanoma Brain Metastasis: A New Potential Target?International journal of molecular sciences · 2025Review
- Predicting voxel-level dose distributions of single-isocenter volumetric modulated arc therapy treatment plan for multiple brain metastases.Frontiers in oncology · 2024Article
- Impact of Heavy Metals on Glioma Tumorigenesis.International journal of molecular sciences · 2023Review
- The value of DTI: achieving high diagnostic performance for brain metastasis.La Radiologia medica · 2021Article
- Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases.Scientific reports · 2019Observational
- Brain metastasis in pancreatic cancer: Two case reports.Medicine · 2019Article
- Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2017Review
- Neurosurgical management of brain metastases.Clinical & experimental metastasis · 2017Review
- Downregulation of EGFR in a metastatic brain lesion of EGFR-mutated non-small cell lung cancer using a tyrosine kinase inhibitor: A case report.Oncology letters · 2017Article
- Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors.The oncologist · 2017Article
- Clinical investigation into the initial diagnosis and treatment of 539 patients with stage IV lung cancer.OncoTargets and therapy · 2017Article
- Sunitinib tissue distribution changes after coadministration with ketoconazole in mice.European journal of drug metabolism and pharmacokinetics · 2016Article
- NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.BMC cancer · 2015Article
- In vivo delivery of miRNAs for cancer therapy: challenges and strategies.Advanced drug delivery reviews · 2015Review
- Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors.Journal of neuro-oncology · 2014Article
- In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy.Oncotarget · 2014Article
- Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors.Investigational new drugs · 2014Article
- Treatment of single or multiple brain metastases by hypofractionated stereotactic radiotherapy using helical tomotherapy.International journal of molecular sciences · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain metastases (BM) are the most common intracranial tumors and their incidence is increasing. Untreated brain metastases are associated with a poor prognosis and a poor performance status. Metastasis development involves the migration of a cancer cell from the bulk tumor into the surrounding tissue, extravasation from the blood into tissue elsewhere in the body, and formation of a secondary tumor. In the recent past, important results have been obtained in the management of patients affected by BM, using surgery, radiation therapy, or both. Conventional chemotherapies have generally produced disappointing results, possibly due to their limited ability to penetrate the blood-brain barrier. The advent of new technologies has led to the discovery of novel molecules and pathways that have better depicted the metastatic process. Targeted therapies such as bevacizumab, erlotinib, gefitinib, sunitinib and sorafenib, are all licensed and have demonstrated improved survival in patients with metastatic disease. In this review, we will report current data on targeted therapies. A brief review about brain metastatic process will be also presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.